Investor Relations News Releases News Releases April 10, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 Additional Formats PDF Version March 25, 2021 Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Additional Formats PDF Version March 11, 2021 Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting Additional Formats PDF Version March 1, 2021 Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies Additional Formats PDF Version February 23, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th Additional Formats PDF Version February 17, 2021 Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version February 12, 2021 Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version January 25, 2021 Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 21, 2021 Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version September 9, 2020 Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Additional Formats PDF Version August 12, 2020 Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version June 22, 2020 Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020 Additional Formats PDF Version June 8, 2020 Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th Additional Formats PDF Version May 29, 2020 Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity Additional Formats PDF Version May 14, 2020 Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 Additional Formats PDF Version May 12, 2020 Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version May 4, 2020 Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020 Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
Investor Relations News Releases News Releases April 10, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 Additional Formats PDF Version March 25, 2021 Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Additional Formats PDF Version March 11, 2021 Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting Additional Formats PDF Version March 1, 2021 Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies Additional Formats PDF Version February 23, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th Additional Formats PDF Version February 17, 2021 Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version February 12, 2021 Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version January 25, 2021 Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 21, 2021 Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version September 9, 2020 Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Additional Formats PDF Version August 12, 2020 Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version June 22, 2020 Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020 Additional Formats PDF Version June 8, 2020 Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th Additional Formats PDF Version May 29, 2020 Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity Additional Formats PDF Version May 14, 2020 Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 Additional Formats PDF Version May 12, 2020 Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version May 4, 2020 Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020 Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
News Releases April 10, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 Additional Formats PDF Version March 25, 2021 Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Additional Formats PDF Version March 11, 2021 Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting Additional Formats PDF Version March 1, 2021 Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies Additional Formats PDF Version February 23, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th Additional Formats PDF Version February 17, 2021 Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version February 12, 2021 Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version January 25, 2021 Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 21, 2021 Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version September 9, 2020 Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Additional Formats PDF Version August 12, 2020 Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version June 22, 2020 Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020 Additional Formats PDF Version June 8, 2020 Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th Additional Formats PDF Version May 29, 2020 Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity Additional Formats PDF Version May 14, 2020 Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 Additional Formats PDF Version May 12, 2020 Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version May 4, 2020 Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020 Additional Formats PDF Version
April 10, 2021 Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1 Additional Formats PDF Version
March 25, 2021 Phio Pharmaceuticals Reports 2020 Year End Financial Results and Provides Business Update Additional Formats PDF Version
March 11, 2021 Phio Pharmaceuticals To Present New Data on PD-1 Targeting INTASYL at the 2021 American Association for Cancer Research (AACR) Annual Meeting Additional Formats PDF Version
March 1, 2021 Phio Pharmaceuticals and AgonOx, Inc. Announce Collaboration on Clinical Development of Novel T Cell-based Cancer Immunotherapies Additional Formats PDF Version
February 23, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright Global Life Sciences Conference on March 9th-10th Additional Formats PDF Version
February 17, 2021 Phio Pharmaceuticals Announces Closing of $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version
February 12, 2021 Phio Pharmaceuticals Announces $7.7 Million Registered Direct Offering of Common Stock Priced At-the-Market Additional Formats PDF Version
January 25, 2021 Phio Pharmaceuticals Announces Closing of $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version
January 21, 2021 Phio Pharmaceuticals Announces $14.0 Million Private Placement Priced At-the-Market Additional Formats PDF Version
January 4, 2021 Phio Pharmaceuticals to Participate in the H.C. Wainwright BioConnect 2021 Conference Additional Formats PDF Version
November 19, 2020 Phio Pharmaceuticals to Participate in the 3rd Annual Evercore ISI HealthCONx Conference Additional Formats PDF Version
November 10, 2020 Phio Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version
November 9, 2020 Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment Additional Formats PDF Version
October 26, 2020 Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Additional Formats PDF Version
September 9, 2020 Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Additional Formats PDF Version
August 12, 2020 Phio Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version
June 22, 2020 Phio Presents Additional Data Supporting Potential of TIGIT Targeting INTASYL Compound in the Tumor Microenvironment at AACR 2020 Additional Formats PDF Version
June 8, 2020 Phio Pharmaceuticals to Host Key Opinion Leader Call on Intratumoral Therapy with Self-Delivering RNAi on Friday, June 12th Additional Formats PDF Version
May 29, 2020 Phio Announces Positive In Vivo Data on the Intratumoral Use of INTASYL Compounds Showing Strong Antitumor Activity Additional Formats PDF Version
May 14, 2020 Phio Presents Data on INTASYL as an Alternative to Genetic Modification to Improve Cell-based Immunotherapy at ASGCT 2020 Additional Formats PDF Version
May 12, 2020 Phio Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Additional Formats PDF Version
May 4, 2020 Phio to Present at Upcoming Medical Meetings and Investor Conference in Spring 2020 Additional Formats PDF Version
